BackgroundIgA nephropathy (IgAN) exhibits a highly variable clinical course. As responses to immunosuppressive therapy remain inconsistent, reliable prognostic markers are critically required to identify patients who can show a good response to immunosuppressive treatments.MethodsThis prospective cohort study enrolled adults with biopsy-proven IgAN from 2010-2020.
Good prognosis was defined as a ≥50% reduction in the urine protein-to-creatinine ratio (uPCR) or <0.5 g/g with preserved estimated glomerular filtration rate 1 year after biopsy. Serum and urine cytokines/chemokines (TGF-β1, MCP-1, RANTES, and VEGF) and intrarenal CD45+, CD3+, CD20+, and Ki-67+ cells were analyzed.ResultsAmong the 202 patients, 120 (59.4%) had a good prognosis and showed a significantly lower risk of end-stage kidney disease over a 10-year follow-up.
Multivariable analyses identified immunosuppressive therapy, low histologic grade, lower uPCR, absence of hypertension, higher serum TGF-β1 levels, and reduced intrarenal CD45+ and CD3+ cell infiltration as independent predictors of good prognosis.
Frontiers in Immunology published a clinical update in Infectious Disease on 24 Jun 2026.
The item focuses on Biomarkers predicting good prognosis among patients receiving immunosuppressive treatment in IgA nephropathy: the promising role of serum TGF-β1 and MCP-1.
Review the original article for the full source wording and details.